Trial Summary:

The aim of this study is to assess the activity of anastrozole, in women with oestrogen-receptor- or progesterone-receptor-positive recurrent or metastatic gynaecological cancers. It includes selected patients with epithelial ovarian cancer, endometrial cancers, miscellaneous gynaecological sarcomas and granulosa and sex-cord stromal tumours of the ovary.

Supported By:

Cancer Australia, NCGC, AstraZeneca

Eligibility:

Women with potentially hormone-responsive gynaecological cancers

Registration ID:

ACTRN12610000796088

Participation:

International

Australian Lead Group:

ANZGOG

Status:

Closed

Activation Date:

16/12/2011

Chairs:

Michael Friedlander (Australia)

Contact:

paragon.study@sydney.edu.au